ReviewJournal of nanobiotechnology2025
Sonodynamic biomimetic-nanomedicine fight cancers.
Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Ultrasound-Responsive Engineered Bacteria for Targeted Cancer Therapy: Strategies, Mechanisms, and Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Biomimetic PD-1-nanovesicles inducing tri-modal sonodynamic-chemo-immunotherapy for breast cancer therapy and lung metastasis inhibition.Journal of nanobiotechnology · 2026Article
- Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment.Frontiers in immunology · 2026Review
- From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy.International journal of nanomedicine · 2026Review
- Exosome-Enhanced Sonodynamic Therapy in Cancer: Emerging Synergies and Modulation of the Tumor Microenvironment.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Sonodynamic therapy (SDT) represents an innovative oncological treatment modality that harnesses the synergistic effects of low-intensity ultrasound and sonosensitizers to kill tumor cells. However, this dynamic therapeutic strategy faces multiple obstacles, including physicochemical barriers in the tumor microenvironment (TME) and the potential toxicity of off-target sonosensitizers, which may accumulate in off-target sites and be non-specifically activated by ultrasound, leading to damage of normal tissues. Recently, biomimetic-nanomedicine platforms, specifically designed to target the TME challenges, have emerged as a potent solution, enabling the development of SDT that enhance therapeutic outcomes, which even derives the concept of the sonodynamic biomimetic-nanomedicine (SBNM). In light of the states, we herein aim to summarize a cutting-edge review on the rapid advances of SBNM. Firstly, tumor-killing mechanisms and development and classification of sonosensitizers are outlined. In addition, recent progresses in various biomimetic-nanomedicines, containing red blood cell membrane-coated, immune cell membrane-coated, cancer cell membrane-coated, hybrid membrane-coated, exosomal and microbial mimicking, are described in the development of preclinical research. Importantly, we offer an in-depth presentation for the superiority of SBNM designed to address physicochemical barriers of TME and abnormalization of the anti-tumor immunity. Last but not least, the challenges and perspectives related to SBNM are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.